Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVRiC: Acalabrutinib Plus Venetoclax for Relapsed CLL/SLL
NCT07024706Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of acalabrutinib tablet (Variant 1) and venetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 cohorts), sponsored by AstraZeneca. Primary endpoint: Overall Response Rate. Started Jun 2026; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07024706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024706.